Abivax S.A. (ABVX) - מקדם חוב לטווח ארוך להון

ABIVAX (ABVX) specializes in developing advanced immune-based drugs. The asset's market value trend confirms management's ability to attract investment for final-stage trials while maintaining high data transparency. The business is currently implementing automated molecule screening to reduce primary analysis costs. Revenues rely on government procurement of therapies for intestinal inflammation, with the indicator standing at 0.00.

The development of the patent portfolio and the battle for biotech leadership at ABIVAX (ABVX) are reflected in the long-term debt financial leverage ratio. The ratio of liabilities with a maturity of more than one year to equity determines the company's degree of dependence on borrowed capital, allowing investors to assess the balance between aggressive infrastructure expansion and the risk of losing financial stability during external shocks.